Holocene Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
Holocene Advisors's ALNY Position: Q3 2026 in Review
Holocene Advisors opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2026: 217,000 shares worth $53.5M. The stake represents 0.13% of the portfolio and ranks #182 among its holdings. This is a return to the name: Holocene Advisors previously reported a position in ALNY as recently as Q3 2025.
Holocene Advisors first reported a position in ALNY in Q3 2019 and has held it in 11 quarters since. The position peaked at $195M in Q2 2025. 730 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.
- Holocene Advisors held 217,000 shares of Alnylam Pharmaceuticals worth $53.5M as of Q3 2026.
- Alnylam Pharmaceuticals was a new Holocene Advisors position in Q3 2026.
- Alnylam Pharmaceuticals made up 0.13% of Holocene Advisors's portfolio in Q3 2026, its #182 holding.
- Holocene Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2019 and has held it in 11 quarters since.
- Holocene Advisors's Alnylam Pharmaceuticals position peaked at $195M in Q2 2025.
- 730 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.
Based on Holocene Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.